Stellungnahme zur Nutzenbewertung des G-BA von Arzneimitteln gemäß § 35a SGB V Ramucirumab (neues Anwendungsgebiet kolorektales Karzinom)

• 7. Literatur (nach Erstellung der Konsensversion)

• 1 Gesellschaft der epidemiologischen Krebsregister in Deutschland / Robert – Koch Institut: Krebs in Deutschland 2011–2012, Häufigkeiten und Trends: 9. Ausgabe 2015. http://www.ekr.med.uni-erlangen.de/GEKID/
• 2 AWMF S3 Leitlinie Kolorektales Karzinom, 2013. http://www.awmf.org/leitlinien/detail/ll/021-007OL.html
• 3 Schmoll HJ, Aderka D, Van Cutsem E et al ESMO consensus guidelines for management of pa-tients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516
• 4 Hofheinz RD et al Kolonkarzinom, 2016 http://www.dgho-onkopedia.org/de/onkopedia/leitli-nien/kolonkarzinom
• 5 Van Cutsem E, Tabernero J, Lakomy R et al Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-3506
• 6 Bennouna J, Sastre J, Arnold D et al Continuation of bevacizumab after first progression in met-astatic colorectal cancer (ML18147): a randomized phase 3 trial. Lancet Oncol 2013; 14: 29-37
• 7 Tabernero J, Yoshino T, Cohn AL et al Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16: 499-508
• 8 Giantonio BJ, Catalano PJ, Meropol NJ et al Bevacizumab in combination with oxaliplatin, fluor-ouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544